Related Experiment Videos
[Periodic disease of the child]
1Unité de recherche en épidémiologie et immuno-oncologie pédiatriques, faculté de médecine Nord, Marseille, France.
Abstract:
Familial mediterranean fever is a childhood disease which usually starts around the age of 4 years. Its onset is insidious with common and misleading symptoms such as fever and abdominal pain. Accordingly, this disease is often recognized belatedly from evocative data from previous history such as the recurrence of attacks, familial descent from certain ethnic groups and the lack of other obvious etiology. The clinical picture within this age group is similar to that observed in adults and does not present any clinical or biological originality. Colchicine remains the only efficient treatment to prevent both acute manifestations and amyloidosis. The former is geared toward its current use among children (growth retardation and gonadic disturbances) and is not really relevant, at least in this particular disease.
Insights
Familial Mediterranean Fever (FMF) is a childhood disease often diagnosed late due to vague symptoms like fever and abdominal pain. Early recognition and colchicine treatment are crucial for managing FMF and preventing complications like amyloidosis.
Area of Science:
- Pediatric Rheumatology
- Genetics
- Internal Medicine
Context:
- Familial Mediterranean Fever (FMF) is a genetic autoinflammatory disorder.
- It typically manifests in childhood with nonspecific symptoms like fever and abdominal pain.
- Delayed diagnosis is common due to the insidious onset and mimicry of other conditions.
Purpose:
- To describe the clinical presentation and diagnostic challenges of FMF in children.
- To highlight the importance of recognizing characteristic historical features for timely diagnosis.
- To emphasize the role of colchicine in managing FMF.
Summary:
- FMF in children presents similarly to adults, often with recurrent fever and abdominal pain.
- Diagnosis relies on identifying patterns of recurrent attacks, family history, and ethnic background.
- Colchicine is the established treatment to prevent acute attacks and long-term complications such as amyloidosis.
Impact:
- Improved understanding of FMF in pediatric populations.
- Facilitates earlier diagnosis and intervention, potentially reducing long-term morbidity.
- Reinforces the critical role of colchicine in FMF management, even in children.